Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
102.94
-1.89 (-1.80%)
Feb 25, 2026, 3:43 PM EST - Market open
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
809
Market Cap
19.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| Genmab | 3.72B |
| BioNTech SE | 3.70B |
| BioMarin Pharmaceutical | 3.22B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 845.52M |
RVMD News
- 23 hours ago - Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 6 days ago - Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 - GlobeNewsWire
- 14 days ago - Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 20 days ago - Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 26 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 4 weeks ago - Revolution Medicines Stock Sinks After Merck Deal Talks Collapse - Benzinga
- 4 weeks ago - Merck no longer in talks to buy Revolution Medicines, WSJ reports - Reuters
- 4 weeks ago - Merck No Longer in Talks to Buy Revolution Medicines - WSJ